| 39.06 Delayed Data As of Jan 18 |  +0.08 / +0.21%Today’s Change | 34.89 Today|||52-Week Range 42.36 | +2.22% Year-to-Date |
| Pharma Stock Roundup: Lilly to Buy Loxo for $8B, M&A in Focus at JP Morgan Meet Jan 11 / Zacks.com - Paid Partner Content | The Zacks Analyst Blog Highlights: Bristol-Myers, Celgene, Lilly and Glaxo Jan 09 / Zacks.com - Paid Partner Content |
| New Strong Sell Stocks for January 11th Jan 11 / Zacks.com - Paid Partner Content | Emergent (EBS) Up on '19 View, Posts Preliminary '18 Results Jan 08 / Zacks.com - Paid Partner Content |
| 4 Pharma & Biotech Pipeline Areas to Keep an Eye on in 2019 Jan 11 / Zacks.com - Paid Partner Content | Crowded Cancer Space Triggers Big M&A Deals: More in Store? Jan 08 / Zacks.com - Paid Partner Content |
| Big Pharma CEOs Indicate More M&A Deals at JP Morgan Meeting Jan 10 / Zacks.com - Paid Partner Content |
| Previous close | 38.98 |
| Today’s open | 39.05 |
| Day’s range | 38.92 - 39.22 |
| Volume | 5,922,794 |
| Average volume (3 months) | 3,304,414 |
| Market cap | $100.5B |
| Earnings growth (last year) | +59.84% |
| Earnings growth (this year) | -3.71% |
| Earnings growth (next 5 years) | +3.50% |
| Revenue growth (last year) | +3.58% |
| P/E ratio | 40.0 |
| Price/Sales | 2.25 |
| Price/Book | -- |
| Today’s change | Today’s % change | |
|---|---|---|
| AZNAstraZeneca | +0.26 | +0.72% |
| SNYSanofi | -0.57 | -1.36% |
| LLYEli Lilly and Co | -2.57 | -2.16% |
| BMYBristol-Myers Squibb | +0.52 | +1.05% |
| Next reporting date | February 6, 2019 |
| EPS forecast (this quarter) | $0.67 |
| Annual revenue (last year) | $38.9B |
| Annual profit (last year) | $2.0B |
| Net profit margin | 5.08% |
Sector Health Technology |
Industry Pharmaceuticals: Major |
Chief Executive Officer & Executive Director Emma Walmsley |
Chief Financial Officer & Executive Director Simon Paul Dingemans |
Corporate headquarters Brentford, Greater London |
